Ruth M. Rothstein CORE Center

Recent papers from Ruth M. Rothstein CORE Center

1. Real‐world use and effectiveness of fostemsavir in a US clinical setting: Insights from Trio Health HIV Research NetworkHIV Medicine · 2026
2. Virologic Outcomes With Lenacapavir in People With Human Immunodeficiency Virus: A Multicenter Real-World StudyOpen Forum Infectious Diseases · 2026
3. The COMEBACK Study: Social Determinants of Health Impact on Virologic Suppression in a 48-Week Low-Barrier-Care Study of Rapid Antiretroviral Therapy Reinitiation Among Persons with HIV Lost-to-CareOpen Forum Infectious Diseases · 2026
4. P-362. Utilization of a Safety-Net Health System to Offer Comprehensive Migrant Health Screening, Identify People Living with HIV (PLWH) and Provide Rapid Access to HIV CareOpen Forum Infectious Diseases · 2026
5. Developing a Novel Mobile App to Support HIV Testing and Pre-Exposure Prophylaxis Uptake Among Men Who Have Sex With Men: Formative and Technical Pilot StudyJMIR Human Factors · 2025
6. Real-World Use of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis: Data from Trio Health CohortOpen Forum Infectious Diseases · 2025
7. Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV ClinicJAIDS Journal of Acquired Immune Deficiency Syndromes · 2024
8. Hematopoietic stem cell transplantation and cellular therapy in persons living with HIVCurrent Opinion in Infectious Diseases · 2024
9. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical PharmacyPharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
10. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summaryPharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
11. Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIPPLoS Pathogens · 2024
12. Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use DisorderSubstance Abuse · 2023
13. Access to healthcare among sexual and gender minority youth at risk for HIV: barriers and experiences of discriminationAIDS Care · 2023
14. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumJournal of Clinical Oncology · 2023
15. Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?Therapeutic Advances in Infectious Disease · 2023
16. Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)Open Forum Infectious Diseases · 2022
17. The ATEAM study: Advances in technology to enhance PrEP adherence monitoring ( ATEAM ) among young men who have sex with menClinical and Translational Science · 2022
18. COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccinePLoS ONE · 2022
19. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trialThe Lancet Microbe · 2022
20. HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trialAddiction · 2022